Evaxion Biotech reports Q4 EPS (7c) vs (17c) last year

Reports Q4 revenue $122,000 vs $73,000 last year. “Evaxion has made significant progress over the past 15 months and the company has never been stronger fundamentally. We maintain our strong momentum in strategy execution and have already achieved our first 2025 company milestone with the completion of dosing in the EVX-01 phase 2 trial in January. Having demonstrated our ability to derive value from both our AI-Immunology(TM) platform and our pipeline, we continue our efforts to create long-term value based on our multi-partner strategy. We are confident in our ability to deliver on our 2025 milestones focusing on business development, our platform and pipeline and in doing so further driving long-term value creation,” says Christian Kanstrup, CEO of Evaxion.